RxDoctor Payments Data

Gregg Klosener, DO

Family Medicine · Kansas City, MONPI 1225095920

Payments from drug & device makers

$10,681in general payments, 2019–2025

Across 566 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$944
  • Lilly USA, LLC$890
  • Amgen$662
  • Pfizer$604
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$10,666100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,681 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$94,873
Medicare patients
239
Services billed
2,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$80,492
JardianceEmpagliflozin82$77,907
FarxigaDapagliflozin Propanediol65$76,475
EliquisApixaban91$76,405
MounjaroTirzepatide38$40,875
TrulicityDulaglutide19$32,958
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$31,656
ProliaDenosumab18$30,965
RybelsusSemaglutide12$20,547
JanuviaSitagliptin Phosphate12$15,169
MyrbetriqMirabegron19$13,398
Tresiba Flextouch U-100Insulin Degludec13$11,934
Aimovig AutoinjectorErenumab-Aooe14$9,622
ArexvyRsvpref3 Antigen/As01e/Pf34$9,473
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$944$101,03972 claims
Boehringer IngelheimJardiance, Spiriva Respimat$393$84,76095 claims
AstraZenecaFarxiga, Symbicort$1,611$83,53778 claims
PfizerEliquis, Paxlovid$604$77,834107 claims
Lilly USA, LLCMounjaro, Trulicity$890$73,83457 claims
GSKTrelegy Ellipta, Arexvy$149$41,12973 claims
AmgenProlia$662$30,96518 claims
MerckJanuvia$276$15,16912 claims
Astellas Pharma US IncMyrbetriq$98$13,39819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →